Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005940 (bone disease)
 7,459 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The fluorescent antibody technique using both monoclonal and specific polyclonal virus antibodies was applied to investigate the nature of the inclusions seen in the abnormal osteoclasts associated with Paget's bone disease. The results show that antigens of measles virus, simian virus 5 (SV5) and human parainfluenza virus type 3 (PF3) could be detected in the osteoclasts but not in control bone cells. Measles and SV5 nucleoprotein (NP) and haemagglutinin-neuraminidase (HN) antigens were apparently present in all the cases of Paget's disease examined, whereas PF3 NP and HN antigens were present only in some of the cases. These investigations suggest that paramyxoviruses may play a role in the aetiology of the bone disease.
 ...
PMID:Paramyxovirus antigens in osteoclasts from Paget's bone tissue detected by monoclonal antibodies. 299 50

Evidence is presented in this paper which supports the hepatogenic theory for the mechanism by which the level of serum alkaline phosphatase is raised in liver disease and provides additional evidence that serum phosphatase is not excreted in the bile. By starch gel and paper electrophoresis the normal serum alkaline phosphatase isoenzyme is shown to be rarely present in hepatic bile. The action of neuraminidase demonstrates that beta-globulin isoenzymes of liver and bone are not identical. From these results a theory which clarifies the rationale of the elevation of alkaline phosphatase in bone and liver disease is postulated. The proposed mechanism may be summarized as follows. The normal serum level is the result of two factors, the rate of release of the enzyme from the tissues, principally liver and bone, and the rate of inactivation of the enzymes in the serum and body protein pool. In osteoblastic bone disease the elevated level is due to the rate of release of the enzyme exceeding the rate of inactivation. The raised level does not indicate an inability of the liver to excrete the enzyme via the biliary tract. In liver disease the increase in serum levels is a result of increased liberation of the enzyme from the sinusoidal surface of the liver cell and of regurgitation of the biliary isoenzyme back into the serum.
 ...
PMID:An interpretation of the elevation of serum alkaline phosphatase in disease. 560 83

Bone alkaline phosphatase is a marker of osteoblast activity. In order to study the posttranscriptional modification (glycosylation) of bone alkaline phosphatase in bone disease, we investigated the relationship between mass and catalytic activity of bone alkaline phosphatase in patients with osteoporosis and hyperthyroidism. Serum bone alkaline phosphatase activity was measured after lectin precipitation using the Iso-ALP test kit. Mass concentration of bone alkaline phosphatase was determined with an immunoradiometric assay (Tandem-R Ostase). In general, serum bone alkaline phosphatase mass and activity concentration correlated well. The activity : mass ratio of bone alkaline phosphatase was low in hyperthyroidism. Activation energy of the reaction catalysed by bone alkaline phosphatase was high in osteoporosis and in hyperthyroidism. Experiments with neuraminidase digestion further demonstrated that the thermodynamic heterogeneity of bone alkaline phosphatase can be explained by a different glycosylation of the enzyme.
 ...
PMID:Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone disease. 786 22